What is the difference between a feasibility study and a pilot study in medical devices?

The terms overlap in informal usage but have distinct meanings. A feasibility study is the pre-development assessment of whether a device concept can be built and commercialized. A pilot study (or pilot clinical study) is an early-stage clinical study, usually small, that tests a device in a limited patient population to evaluate initial safety and function before a larger pivotal study. A pilot study is a regulated clinical activity. A feasibility study is a business and engineering assessment.

Does the FDA require a formal feasibility study before a 510(k)?

No. The FDA does not require a formal pre-development feasibility study before a 510(k) submission. However, the FDA's Early Feasibility Study pathway under an IDE is a formal process for first-in-human studies when pre-clinical data is limited. For most 510(k) devices, feasibility testing is an internal risk management and development-planning activity.

What is an IDE and when is it required for feasibility studies?

An Investigational Device Exemption (IDE) is an FDA authorization to use an investigational device in a clinical study. An IDE is required for significant-risk device studies and for Early Feasibility Studies. It is not required for all bench or pre-clinical feasibility testing, or for non-significant-risk device studies that are exempt from IDE requirements. The IDE requirements are at 21 CFR Part 812 (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-812).

How long does a feasibility study take?

A purely internal technical and commercial feasibility assessment can be completed in four to twelve weeks depending on the complexity of the device and the depth of clinical and market research required. An FDA Early Feasibility Study under an IDE has a longer timeline: preparing the IDE application, receiving FDA authorization (typically 30 days from submission if the FDA does not place the study on hold), completing IRB review, enrolling subjects, and analyzing results can take 12 to 24 months or more for a small first-in-human study.

What is ISO 14971 and how does it relate to feasibility?

ISO 14971:2019 is the current edition of the international standard for the application of risk management to medical devices (https://www.iso.org/standard/72704.html). A full ISO 14971 risk management process is applied throughout the device development lifecycle, from concept through post-market surveillance. At the feasibility stage, a preliminary hazard analysis consistent with ISO 14971 principles identifies the highest-risk design features early, when design changes are least costly. It is not a substitute for a full risk management file, which is required for regulatory submissions.

How do feasibility study results affect my marketing program?

Feasibility study outputs define the device's performance envelope, its differentiators from existing solutions, and the clinical evidence that supports those differentiators. These become the inputs for product positioning, sales messaging, and the claims infrastructure for your marketing program. Feasibility data that demonstrates a meaningful clinical performance advantage over the predicate or current standard of care is a marketing asset, not just a regulatory one, provided those claims are consistent with the cleared or approved indications for use.

Can I use feasibility study data in my marketing materials?

With care. Feasibility study data can be cited in marketing materials if the data is published, peer-reviewed, or publicly available, and if the claims derived from it are consistent with the device's cleared or approved indications for use. Promotional claims must not extend beyond the cleared intended use, and early-stage study data (small sample sizes, limited follow-up) should be described with appropriate context about the study design and limitations. Your regulatory counsel should review any proposed use of clinical study data in promotional materials.

Medical Device Feasibility Study: What It Is, What It Covers, and When You Need One

Direct answer: A medical device feasibility study is an early-stage evaluation designed to confirm that a device concept can be built, that it performs its core function at a basic level, and that the clinical and commercial case for development is sound before significant resources are committed. It has two distinct dimensions: technical feasibility (can this device be built and does it work?) and commercial feasibility (is there a market and a viable business model?). The FDA has a specific Early Feasibility Study (EFS) pathway for first-in-human studies under an IDE when a device is not yet ready for a pivotal trial. (As of July 2026.)

The decision to move from concept to full development is one of the most consequential in a medical device company's lifecycle. It is also where teams most commonly overcommit. A device that looked promising on paper can encounter unexpected manufacturing constraints, material performance limits, or regulatory pathway mismatches that fundamentally change the development timeline and capital requirement.

A feasibility study is the structured process for surfacing those problems before committing the resources it takes to solve them.

Two Types of Feasibility: Technical and Commercial

Medical device feasibility analysis covers two related but distinct questions. Conflating them produces a study that answers one and ignores the other.

Technical feasibility asks: Can this device be built with available materials and manufacturing processes, and does it perform its core function at a level consistent with the clinical need? A technical feasibility assessment evaluates engineering constraints, material selection, manufacturing processes, miniaturization requirements (if applicable), power requirements, biocompatibility considerations, sterility requirements, and any fundamental physics or chemistry constraints on the design.

Commercial feasibility asks: Is there a market large enough to support a commercial device company in this space, can the device be manufactured at a cost that supports a viable price point, and does the economic environment for adoption (reimbursement, hospital budget authority, competitive landscape) allow the business to scale? Commercial feasibility is not a market research exercise in the abstract. It must be grounded in the specific clinical environment where the device will be used and the specific purchasing dynamics of that environment.

Both types of feasibility need to be positive before full development is justified. A technically brilliant device without a viable commercial path will fail. A commercially attractive market without a technically buildable solution produces only a pitch deck.

What a Technical Feasibility Assessment Covers

A technical feasibility assessment at the pre-development stage is not a full verification and validation study. It is a targeted evaluation designed to identify the highest-risk technical questions before investing in a full development program.

Core function testing. Can a prototype or proof-of-concept device demonstrate the basic function the clinical need requires? This does not need to be a device manufactured to production specifications. It needs to demonstrate that the underlying physical or engineering principle works.

Material and component selection. What materials will contact the patient, and are they biocompatible under the relevant ISO 10993 framework? What components are commercially available, and do they meet the performance and reliability requirements? Are there supply chain risks associated with any critical components?

Manufacturing process review. Can the device be manufactured at acceptable quality levels using available processes? Some device designs are feasible on the bench but difficult to manufacture repeatably at commercial volumes. Contract manufacturers with experience in the relevant device category (orthopedic implants, electrosurgical devices, drug-device combinations, SaMD) can often provide early manufacturing feasibility input without a full development contract.

Regulatory risk identification. What is the likely device classification, and what performance data will the FDA likely require for market authorization? The regulatory evidence requirements vary significantly by device class and therapeutic area. Identifying the likely data package early allows the development program to be designed to generate that data efficiently. The FDA's list of recognized consensus standards (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/search.cfm) indicates what performance standards are likely to apply.

Failure mode identification. What are the most likely ways this device could fail in clinical use, and can the current design concept withstand those failure modes? Early failure mode analysis (a precursor to full FMEA under ISO 14971) identifies the design features most likely to require iteration.

What a Commercial Feasibility Assessment Covers

Market sizing. How many patients annually undergo the procedure or experience the condition the device addresses, and what fraction of those are addressable by your device in its initial intended use? Market sizing at the feasibility stage does not need to be precise. It needs to be directionally correct and sufficient to determine whether the opportunity can support a commercial company.

Price point and margin analysis. At what average selling price would the device need to be sold to support the business? Can the device be manufactured at a cost that generates an acceptable gross margin at that price? Capital equipment and consumable device economics are structured differently, and the feasibility assessment should reflect the appropriate model.

Reimbursement landscape. Is there an existing CPT code or DRG that covers the procedure where the device will be used? If not, what is the pathway to securing reimbursement coverage, and how long will it take? The absence of existing reimbursement is not a disqualifier, but it is a significant variable that affects commercialization timeline and capital requirements. CMS coverage and reimbursement information is available at https://www.cms.gov/medicare/payment.

Competitive and substitution analysis. Who else is selling into this space, and what would it take for a hospital or practice to switch from existing solutions to yours? The switching cost is not only financial: it includes clinician training, workflow disruption, and the institutional inertia of existing vendor relationships.

Regulatory and reimbursement timeline modeling. How long will it realistically take to reach the market, and what does that mean for the capital plan? A device that requires a 510(k) and can reach market in 18 months has a very different capital and cash flow profile than a device requiring a PMA with a three-year IDE clinical trial. This timeline feeds directly into investor conversations and burn rate planning.

The FDA's Early Feasibility Study (EFS) Pathway

When a device requires first-in-human testing before a full pivotal trial, the FDA has established a specific pathway: the Early Feasibility Study (EFS). This is a formal regulatory mechanism, not just an informal industry term.

An EFS is a limited first-in-human study of a device that may not yet have extensive pre-clinical or engineering data. The FDA describes the purpose of an EFS as providing early clinical information to guide device development and clinical study design when the device design is not sufficiently developed to support a traditional pivotal study (FDA guidance: https://www.fda.gov/media/116618/download). EFS studies are typically small, usually enrolling a limited number of subjects (often on the order of 10 to 15) across a small number of sites, and are designed to assess safety and initial device function, not to demonstrate substantial equivalence or generate pivotal safety and effectiveness data. FDA's Early Feasibility Studies guidance frames them as limited in enrollment and does not fix a single universal subject cap; the specific number is set by the study design FDA authorizes.

An EFS requires an Investigational Device Exemption (IDE) under 21 CFR Part 812. The IDE application (https://www.fda.gov/medical-devices/investigational-device-exemption-ide/investigational-device-exemption-ide-home) must include the device description, proposed clinical protocol, investigator information, informed consent procedures, IRB approval, and monitoring plan.

The distinction between an EFS and a traditional feasibility study (the internal technical/commercial assessment described above) matters: an EFS is a formal FDA-regulated clinical study. An internal feasibility assessment is a business and engineering decision-making tool. Both are called "feasibility studies" in medtech contexts but they are different activities.

When to Conduct a Feasibility Study

Feasibility assessment should happen before full development begins. That means before significant engineering resource is committed to a specific design, before manufacturing tooling is purchased, and before a clinical study is initiated without adequate prior data to support the study design.

The most common mistake is treating feasibility as a phase that can be compressed or skipped when a team is eager to show progress. The cost of discovering a critical feasibility problem at the verification and validation stage, or during a pivotal clinical study, is orders of magnitude higher than discovering it in a structured pre-development assessment.

Signs that a more rigorous feasibility study is warranted:

The device uses a novel material or manufacturing process without a track record in the intended use environment
The device is in a new-to-market category without a well-established predicate
The clinical evidence required for the likely regulatory pathway is not yet characterized
The primary reimbursement code for the target procedure is under active coverage reconsideration
The device requires first-in-human testing to confirm basic safety before full development can proceed

From Feasibility to Positioning: The Marketing Connection

Feasibility study outputs have a direct connection to marketing strategy that most device companies underutilize.

The technical feasibility assessment identifies the device's key performance characteristics and differentiators against existing solutions. Those differentiators are the foundation of product positioning. The commercial feasibility assessment identifies the buyer, the competitive landscape, the price point, and the reimbursement environment. That is the foundation of the go-to-market strategy.

Companies that start marketing planning at or shortly after the feasibility stage arrive at launch with messaging grounded in their actual clinical evidence, not retrofitted from a product spec sheet. Buzzbox Media works with medical device companies at every stage of the launch lifecycle. If you want to understand how feasibility findings connect to your go-to-market strategy and FDA-compliant marketing program, book a 30-minute call at https://www.buzzboxmedia.com/book.